A controlled study of patients with advanced EGFR/ALK wild-type NSCLC who received PD-1/PD-L1 inhibitors showed that compared with normal controls, NSCLC patients had more than 150 differentially expressed exosomal microRNAs. The gene discussed is CD274; the disease is non-small cell lung carcinoma.